More Videos
|
CNBC'S MOST SHARED
- Go for Good Energy Companies: Bob Doll
- Yoshikami: A No Jobs Recovery Is Bad News
- Market 360: The Week's Best & Worst
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Bank of America Topples UBS as World Wealth Manager
- Plan to Sell General Motors' Assets Is Approved
- UBS Says It Stays Committed to US Brokerage
- UK Spy Chief's Wife Posts Life on Facebook
- China Launches Major Step to Yuan Internationalization
- Alcoa to Post Loss — What Does This Mean?
- A Goldman Trading Scandal?
- Nigeria Rebels Attack Oil Facility, Hijack Tanker
- China Says 140 Die in Rioting
RSS FEED
Text Size 
 |
] put out a press release this morning announcing that an unidentified institutional investor is going to buy eight million shares and warrants to buy as much as another eight million for a total infusion of $47 million. DNDN says it will use the money to "fund our commercialization activities for Provenge," among other things. Provenge is a therapeutic vaccine for prostate cancer that is in the middle of a crucial clinical trial.
Back in February I blogged about Morgan Stanley and a hedge fund, Visium Asset Management, taking a combined 16.5 percent stake in DNDN. Big investors like that have 45 days to disclose their positions to the Securities and Exchange Commission, so the identity of Dendreon's secret lover could be revealed in the not-too-distant future.
Dendreon can be a very volatile stock. It has a huge short interest or shares that belong to investors who are hoping the price will fall. This is not an investment for the faint of heart. But obviously another one of the "big boys" has a strong ticker.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes